GlassScriptPhysician profile
Jemini G Ignacio
NPI 1912993429
$830.78
in general payments reported to CMS, 2019-2025
13 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.43 · 2023: $160 · 2024: $417 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $213.86 | 2023-2024 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $149.60 | 2024-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $120.60 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.54 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $71.21 | 2023-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $47.43 | 2023-2024 | Farxiga |
| Lundbeck LLC | $31.78 | 2024 | Rexulti |
| Amgen INC. | $24.05 | 2024 | Repatha |
| Glaxosmithkline, LLC. | $23.57 | 2024 | Shingrix, Arexvy |
| Edwards Lifesciences Corporation | $17.94 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Otsuka America Pharmaceutical, INC. | $17.54 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $17.23 | 2025 | Capvaxive, Gardasil 9 |
| Karl Storz Endoscopy-America | $15.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jemini Ignacio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.